The Fly

CymaBay price target raised to $19 from $12 at Piper Sandler

Piper Sandler analyst Yasmeen Rahimi raised the firm’s price target on CymaBay to $19 from $12 to reflect increased confidence in the company and seladelpar’s commercial opportunity, while keeping an Overweight rating on the shares.CymaBay is the firm’s top small cap pick for 2023 for several reasons, namely the recent raise and Kaken deal that removes the cash overhang, Phase 3 RESPONSE that is on track for reporting in Q3 2023, recent epidemiology data suggesting a larger addressable population for seladelpar versus previous predictions, CymaBay’s NDA package that will include over 400 PBC patients in the safety database, and seladelpar that could be the most effective drug in 2L PBC givenits anti-inflammatory effect and benefit on itch reduction giving it a competitive edge.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on CBAY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More